ClinicalTrials.gg
Not yet recruitingNCT07345000Updated Jan 15, 2026

A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia

A Phase 3 interventional study of Romiplostim N01 and Cyclosporine A (CsA) in Treatment-naïve Severe Aplastic Anemia, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing romiplostim in Anemia, Aplastic — 6 open to participants now, 6 under way, 1 of them phase 3. romiplostim · Anemia, Aplastic.

Planned enrollment
Largest of 15
210 · median 35
Started
2026
with 5 others
Phase 3
Only one
of the 15
Registered
10th of 15
by date
Lead sponsor
1 of 15
Qilu Pharmaceutical Co., Ltd.

Among the 15 studies testing romiplostim in Anemia, Aplastic, this one has the largest planned enrollment, is one of 6 that started in 2026, is the only one in phase 3, and was the 10th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

6 of the 15 studies testing romiplostim in Anemia, Aplastic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing romiplostim in Anemia, Aplastic, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter trial designed to evaluate treatment with romiplostim N01+ IST compared with placebo + IST in the participants with treatment-naïve severe aplastic anemia.

03

Conditions studied

  • Treatment-naïve Severe Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥15 years, regardless of sex (subjects ≥18 years old will be enrolled first; enrollment of subjects aged 15-18 years will commence after sufficient PK/PD data are obtained).
  2. Diagnosis of SAA or VSAA according to the British Journal of Haematology (BJH) guidelines. The diagnostic criteria for SAA are as follows:

    ①Bone marrow cellularity \<25% of normal; or between 25% and \<50%, with residual hematopoietic cells comprising \<30%.

    ②Peripheral blood counts must meet at least two of the following three criteria (based on the lowest values from tests within 28 days prior to the first dose):

    1. (ANC) \<0.5×10⁹/L
    2. count (PLT) \<20×10⁹/L
    3. Absolute reticulocyte count (RET) \<60×10⁹/L The diagnostic criterion for VSAA is: meeting the SAA criteria + ANC \<0.2×10⁹/L.
  3. Written

Exclusion criteria

Exclusion Criteria:

  1. History and/or concomitant presence of other primary or secondary bone marrow failure (BMF) syndromes, such as:

    ①Primary: Fanconi anemia, dyskeratosis congenita, congenital amegakaryocytic thrombocytopenia or Shwachman-Diamond syndrome, symptomatic paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), clonal cytopenia of undetermined significance (CCUS), antibody-mediated BMF, idiopathic cytopenia of undetermined significance (ICUS), etc.

    • Secondary: large granular lymphocyte (LGL) leukemia, infiltration of the bone marrow by other systemic , myelofibrosis, and acute hematopoietic arrest, etc.

    Note: Asymptomatic PNH and hepatitis-associated SAA may be included if they meet all other inclusion criteria.

  2. Evidence of clonal cytogenetic abnormalities at screening.
  3. Participation in another clinical trial with drugs or medical devices within 30 days prior to the first dose or within 5 half-lives of the investigational product (whichever is longer).
  4. Previous use of any of the following agents prior to the first dose:

    • ATG/ALG

      • Alemtuzumab

        • Mycophenolate mofetil ④Sirolimus

          • Tacrolimus ⑥High-dose cyclophosphamide (≥45 mg/kg/day)
  5. Cumulative cyclosporine A (CsA) therapy exceeding 4 weeks prior to the first dose. If cumulative use is ≤4 weeks, a of >14 days prior to the first dose is required.
  6. Cumulative use of thrombopoietin receptor agonists (TPO-RAs) for >14 days prior to the first dose, or cumulative use ≤14 days with a washout period of \<14 days, including:

    • Romiplostim / Nplate® (romiplostim)

      • Eltrombopag ③Hetrombopag ④Recombinant human thrombopoietin, etc.
  7. Previous history of hematopoietic stem cell transplantation.
  8. Uncontrolled bleeding and/or infection after standard treatment prior to the first dose [defined as persistent signs/symptoms related to infection without improvement despite appropriate antibiotic and/or other therapy], or requiring intravenous (IV) antibiotic administration.
  9. Concomitant active CMV and EBV infection (positive test).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Romiplostim N01+ IST

    Drug: Romiplostim N01 · Drug: Cyclosporine A (CsA) · Drug: pALG/ rATG

  • Active comparator
    Placebo+ IST

    Drug: Placebo · Drug: Cyclosporine A (CsA) · Drug: pALG/ rATG

Interventions

  • Starting from Day 1 of Week 1, administer the initial dose of romiplostim N01: 10 μg/kg. Platelet count (PLT) must be monitored weekly. The dose should be adjusted based on platelet values (adjusted by 5 μg/kg per change, see the table below for specific rules), administered once weekly, with a maximum dose of 20 μg/kg.

  • Initiate at a dose of 5 mg/kg/day, administered orally in two divided doses (recommended at 12-hour intervals). The dose may be adjusted between 3 and 5 mg/kg/day based on the subject's tolerance.

  • DrugpALG/ rATG

    25 mg/kg/day on Days 1 through 5 of Week 1.

  • DrugPlacebo

    Starting from Day 1 of Week 1, administer the initial dose of placebo: 10 μg/kg. Platelet count (PLT) must be monitored weekly. The dose should be adjusted based on platelet values (adjusted by 5 μg/kg per change, see the table below for specific rules), administered once weekly, with a maximum dose of 20 μg/kg.

  • Initiate at a dose of 5 mg/kg/day, administered orally in two divided doses (recommended at 12-hour intervals). The dose may be adjusted between 3 and 5 mg/kg/day based on the subject's tolerance.

  • DrugpALG/ rATG

    25 mg/kg/day on Days 1 through 5 of Week 1.

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) rate at the 6-month time point of treatment.

    Proportion of subjects achieving hematopoietic complete response at the 6-month. Hematopoietic complete response is defined as: hemoglobin ≥10 g/dL, absolute neutrophil count ≥1×10⁹/L, and platelet count ≥100×10⁹/L.

    Time frame: During 6 months of therapy

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Oct 2029, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 15, 2026
StartEst.
Jan 2026
Primary completionEst.
Oct 2029
CompletionEst.
Aug 2030
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07345000
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Jan 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Aug 2030 (estimated)
Last update
Jan 15, 2026

Study contacts

jun shi, Professor
Contact
shijun@ihcams.ac.cn
022-23608326

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion